Hepatic Arterial Infusion Chemotherapy

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC